Zobrazeno 1 - 10
of 171
pro vyhledávání: '"S, Secondino"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
S. Secondino, V. Grazioli, F. Valentino, M. Pin, A. Pagani, A. Sciortino, C. Klersy, M. G. Callegari, P. Morbini, R. Dore, M. Paulli, P. Pedrazzoli, A. M. D’armini
Publikováno v:
Sarcoma, Vol 2017 (2017)
Introduction. Pulmonary artery sarcoma (PAS) is a rare tumor, whose therapeutic approach is mainly based on surgery, either pneumonectomy or pulmonary endarterectomy (PEA). The prognosis reported in published series is very poor, with survival of 1.5
Externí odkaz:
https://doaj.org/article/db51db0570c84754b49360236787941e
Publikováno v:
Journal of Cancer, Vol 2, Iss 1, Pp 341-346 (2011)
Among the novel biologic therapeutics that will increase our ability to cure human cancer in the years to come, T cell therapy is one of the most promising approaches. However, with the possible exception of tumor-infiltrating lymphocytes therapy for
Externí odkaz:
https://doaj.org/article/d81b4316553e47ec917f44acc0424b33
Autor:
A. Lasagna, D. Lilleri, F. Agustoni, E. Percivalle, S. Borgetto, N. Alessio, G. Comolli, A. Sarasini, F. Bergami, J.C. Sammartino, A. Ferrari, F. Zavaglio, F. Arena, S. Secondino, M. Falzoni, R. Schiavo, G. Lo Cascio, L. Cavanna, F. Baldanti, P. Pedrazzoli, I. Cassaniti
Publikováno v:
ESMO Open
Background The durability of immunogenicity of SARS-CoV-2 vaccination in cancer patients remains to be elucidated. We prospectively evaluated the immunogenicity of the vaccine in triggering both the humoral and the cell-mediated immune response in ca
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A, Lasagna, F, Bergami, D, Lilleri, E, Percivalle, M, Quaccini, N, Alessio, G, Comolli, A, Sarasini, J C, Sammartino, A, Ferrari, F, Arena, S, Secondino, D, Cicognini, R, Schiavo, G, Lo Cascio, L, Cavanna, F, Baldanti, P, Pedrazzoli, I, Cassaniti
Publikováno v:
ESMO Open
Although a full course of coronavirus disease 2019 (COVID-19) vaccine is effective in cancer patients, the duration of the protection and the efficacy of a booster dose against the new variants remain unknown. We prospectively evaluated the immunogen
Autor:
A. Lasagna, S. Secondino, F. Agustoni, T. Monaco, I. Imarisio, A. Pagani, G. Rizzo, R. J. Tancredi, E. Pozzi, E. Ferraris, S. Chiellino, C. Gandini, A. Ferrari, S. G. Brugnatelli, P. Pedrazzoli
Publikováno v:
Annals of Research in Oncology. :56
Autor:
Patrizia Giannatempo, Paolo Pedrazzoli, Christian Chabannon, Lo Vullo S, Andrea Necchi, S. Secondino, Manuela Badoglio, Luigi Mariani, Francesco Lanza, Daniele Raggi, Chiara Bonini, Giovanni Rosti
We aimed to assess the incidence and risk factors of secondary malignancy (SM) in the young adult patients who received high-dose chemotherapy (HDCT) for germ cell tumors (GCT). The EBMT database was interrogated. Criteria for patient selection inclu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92c1d3b1d383a7d3a82178859c0ebe38
http://hdl.handle.net/11392/2416008
http://hdl.handle.net/11392/2416008
Autor:
Manuela Badoglio, Giovanni Rosti, Andrea Necchi, S. Lo Vullo, Patrizia Giannatempo, Paolo Pedrazzoli, Luigi Mariani, Francesco Lanza, Daniele Raggi, S. Secondino
Publikováno v:
Bone marrow transplantation. 52(8)
Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database
Autor:
Valentina Grazioli, Marco Paulli, Antonio Sciortino, Patrizia Morbini, Anna Pagani, Maurizio Pin, Paolo Pedrazzoli, Roberto Dore, Catherine Klersy, S. Secondino, M. G. Callegari, Francesco Valentino, Andrea Maria D'Armini
Publikováno v:
Sarcoma
Sarcoma, Vol 2017 (2017)
Sarcoma, Vol 2017 (2017)
Introduction. Pulmonary artery sarcoma (PAS) is a rare tumor, whose therapeutic approach is mainly based on surgery, either pneumonectomy or pulmonary endarterectomy (PEA). The prognosis reported in published series is very poor, with survival of 1.5